TABLE 4.

Multivariate Analyses for the PSADT Patient Subset (n = 657): nPSA12 as a Continuous Covariate

Variable	HR (95% CI)	P
Biochemical failure (n = 254)*
Increasing PSADT	0.971 (0.963-0.978)	<.0001
Increasing iPSA	1.012 (1.007-1.016)	<.0001
Gleason score ≥7	2.026 (1.531-2.682)	<.0001
Increasing RT dose	0.912 (0.876-0.950)	<.0001
Increasing nPSA12	1.015 (1.003-1.028)	.0147
Distant metastasis (n = 49)*
T3	3.882 (2.028-7.429)	<.0001
Increasing nPSA12	1.036 (1.022-1.051)	<.0001
PSADT	0.783 (0.730-0.839)	<.0001
Cause-specific mortality (n = 17)*
Increasing nPSA12	1.046 (1.030-1.062)	<.0001
T3	3.816 (1.223-11.903)	.0210
Overall mortality (n = 89)*
Increasing nPSA12	1.026 (1.015-1.037)	<.0001
Age	1.072 (1.035-1.111)	.0001
Increasing RT dose	0.912 (0.848-0.980)	.0117
Gleason score ≥7	1.663 (1.042-2.653)	.0329

HR indicates hazards ratio; 95% CI, 95% confidence interval; PSADT, PSA doubling time; iPSA, initial pretreatment PSA; RT dose, radiotherapy dose in Gy; nPSA12, nadir PSA within 12 months of follow-up; Gleason Score.

^*Number of events for each endpoint in parentheses.